Programming gene and engineered-cell therapies with synthetic biology
Name
Weiss-Science-2018-aad1067_CombinedPDF_final.pdf
Description
Main article
Size
2.01 MB
Format
Adobe PDF
Checksum (MD5)
bd5c691a9e2297a636f0521544508c36
Author(s)
Kitada, Tasuku
DiAndreth, Breanna
Teague, Brian Paul
Weiss, Ron
Date Issued
February 2018
Journal
Science
Publisher
American Association for the Advancement of Science (AAAS)
Citation
Kitada, Tasuku et al. “Programming Gene and Engineered-Cell Therapies with Synthetic Biology.” Science 359, 6376 (February 2018): eaad1067 © 2018 The Authors
Version
Author's final manuscript
Abstract
Gene and engineered-cell therapies promise to treat diseases by genetically modifying cells to carry out therapeutic tasks. Although the field has had some success in treating monogenic disorders and hematological malignancies, current approaches are limited to overexpression of one or a few transgenes, constraining the diseases that can be treated with this approach and leading to potential concerns over safety and efficacy. Synthetic gene networks can regulate the dosage, timing, and localization of gene expression and therapeutic activity in response to small molecules and disease biomarkers. Such “programmable” gene and engineered-cell therapies will provide new interventions for incurable or difficult-to-treat diseases.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Synthetic Biology Center
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1126/science.aad1067
